• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Guard Therapeutics

1.59 SEK+6.00 %8.7, 17.29
Less than 1K followers

GUARD

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+6.00 %
+13.57 %
+19.01 %
+7.80 %
+8.16 %
-90.81 %
-76.31 %
-97.54 %
-99.91 %

Guard Therapeutics is engaged in the development of drugs in the field of oxidative stress. The company focuses primarily on research, development and commercialization of drugs that aim to prevent the onset and complications of acute kidney injury. The drug has been shown in preclinical studies to protect exposed tissue and support regenerative processes. The company is headquartered in Lund.

Read more
Market cap
32.07M SEK
Turnover
3.51K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
All
Webcasts
Press releases
ShowingAll content types

Financial calendar
20.7
2026

Extraordinary general meeting '26

20.8
2026

Interim report Q2'26

12.11
2026

Interim report Q3'26

Press release12.06.2026, 08.40

Guard Therapeutics Initiates Transaction Process for the GTX Platform

Guard Therapeutics
Regulatory press release10.06.2026, 19.50

Guard Therapeutics has entered into a conditional agreement for a reverse takeover with Disruptive Pharma

Guard Therapeutics
Regulatory press release09.04.2026, 17.10

Guard Therapeutics provides information regarding observation status on Nasdaq First North Growth Market

Guard Therapeutics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release31.03.2026, 15.45

Guard Therapeutics provides update on strategic review

Guard Therapeutics
Regulatory press release05.02.2026, 16.45

Guard Therapeutics Announces Changes to the Company’s Management Team

Guard Therapeutics
Press release05.02.2026, 16.35

Guard Therapeutics Provides Status Update Regarding Ongoing Strategic Review

Guard Therapeutics
Press release15.01.2026, 16.55

Guard Therapeutics Partners in EU Consortium For Alport Syndrome

Guard Therapeutics
Press release30.12.2025, 14.20

DNB Carnegie Access: Guard Therapeutics: Discontinuing coverage

Guard Therapeutics
Regulatory press release16.12.2025, 14.20

Guard Therapeutics presents the Nomination Committee for 2026

Guard Therapeutics
Press release08.12.2025, 16.00

Guard Therapeutics appoints Redeye as financial advisor in the strategic review

Guard Therapeutics
Regulatory press release05.12.2025, 14.40

Guard Therapeutics changes Certified Adviser to Redeye AB

Guard Therapeutics
Press release05.12.2025, 06.21

DNB Carnegie Access: Guard Therapeutics: Challenging path forward

Guard Therapeutics
Regulatory press release04.12.2025, 19.50

Guard Therapeutics Explores Strategic Alternatives

Guard Therapeutics
Press release04.12.2025, 19.45

Guard Therapeutics Provides Assessment of Full POINTER Study Results

Guard Therapeutics
Press release13.11.2025, 17.17

DNB Carnegie Access: Guard Therapeutics: Awaiting further company communication – Q3 review

Guard Therapeutics
Press release27.10.2025, 09.33

DNB Carnegie Access: Guard Therapeutics: POINTER data – endpoints not met

Guard Therapeutics
Regulatory press release26.10.2025, 11.45

Guard Therapeutics Announces Top-Line Results from Phase 2b POINTER Study

Guard Therapeutics
Press release17.10.2025, 08.00

Guard Therapeutics to Present Late-Breaking Phase 2b POINTER Results at ASN Kidney Week 2025

Guard Therapeutics
Regulatory press release05.10.2025, 14.15

Guard Therapeutics Announces New Positive Efficacy Results from Secondary Analyses of the Phase 2a AKITA Study

Guard Therapeutics
Press release30.09.2025, 12.22

DNB Carnegie Access: Guard Therapeutics: POINTER data preview: high risk, high potential reward - corrected version

Guard Therapeutics